Botulinum toxin type B is a neuromuscular blocking agent indicated for the treatment of cervical dystonia. When injected directly into a muscle, it causes a localised paralysis that gradually reverses over time.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC Group | Classification | |
|---|---|---|
| M03AX01 | Botulinum toxin | M Musculo-skeletal system → M03 Muscle relaxants → M03A Muscle relaxants, peripherally acting agents → M03AX Other muscle relaxants, peripherally acting agents |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Document | Type | Information Source | |
|---|---|---|---|
| NEUROBLOC Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) |
Botulinum toxin type B is an active ingredient of these brands:
Austria (AT)Cyprus (CY)Estonia (EE)Finland (FI)France (FR)Ireland (IE)Japan (JP)Lithuania (LT)Poland (PL)Romania (RO)Spain (ES)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.